MD
Highly rated in
26
conditions

Dr. Matthew S. Davids

Dana-Farber Cancer Institute, Medical Oncology
Boston, MA
Highly rated in
26
conditions
Specialties:Oncology | Hematology Oncology
Experience:18 Years
Clinical Trials:Currently Recruiting for 5 Trials
Accepts:New PatientsMedicare
Highly rated in
26
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

View 25 More Conditions +
Check Dr. Matthew S. Davids' experience treating your condition:
About Dr. Matthew S. Davids

Matthew Davids is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Davids has been practicing medicine for over 18 years and is highly rated in 26 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Davids is currently accepting new patients.

His clinical research consists of co-authoring 147 peer reviewed articles and participating in 15 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Matthew S. Davids it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Matthew S. Davids accepts the following insurance:

  •  Ambetter
  •  Anthem
Call to see if your plan is accepted.
Locations
450 Brookline Ave, Boston, MA 02215
Background & Education
Graduate Institution
Yale University School Of Medicine, 2005
Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Milford Regional Medical Center
Brigham And Womens Hospital
North Shore Medical Center - Salem Hospital
Dana Farber Cancer Institute
Beverly Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials
A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination With PD-1 Antagonist Nivolumab in Patients With Transformed Chronic Lymphocytic Leukemia (Richter's Transformation) or Non-Hodgkin Lymphoma
Enrollment Status: Recruiting
Publish Date: March 24, 2022
Intervention Type: Drug, Biological
Study Drugs: CopanlisibNivolumab
Study Phase: Phase 1
A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome
Enrollment Status: Recruiting
Publish Date: July 07, 2022
Intervention Type: Drug
Study Drugs: DuvelisibVenetoclax
Study Phase: Phase 1/Phase 2
A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide or Pembrolizumab in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.
Enrollment Status: Recruiting
Publish Date: September 28, 2022
Intervention Type: Drug
Study Drugs: NeoVaxCyclophosphamidePembrolizumab
Study Phase: Phase 1
A Phase 2 Study of MRD Adapted Therapy With Venetoclax-obinutuzumab in Patients With High or Intermediate BALL Risk Relapsed or Refractory CLL, With Addition of Acalabrutinib in Patients Who Fail to Achieve MRD Eradication
Enrollment Status: Recruiting
Publish Date: August 16, 2021
Intervention Type: Drug
Study Drugs: VenetoclaxObinutuzumabAcalabrutinib
Study Phase: Phase 2
Venetoclax Plus Dose-adjusted R-EPOCH or R-CHOP for Richter's Syndrome
Enrollment Status: Recruiting
Publish Date: July 13, 2022
Intervention Type: Other, Drug
Study Drug: Venetoclax
Study Phase: Phase 2
A Phase 1b/2 Study of IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia.
Enrollment Status: Active, not recruiting
Publish Date: September 30, 2022
Intervention Type: Drug
Study Drugs: IPI-145 PI3K Delta/Gamma InhibitorFludarabineCyclophosphamideRituximab
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) for Initial Therapy of Chronic Lymphocytic Leukemia
Enrollment Status: Active, not recruiting
Publish Date: December 06, 2022
Intervention Type: Drug
Study Drugs: VenetoclaxObinutuzumabAcalabrutinib
Study Phase: Phase 2
A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Enrollment Status: Active, not recruiting
Publish Date: September 30, 2022
Intervention Type: Drug
Study Drugs: ObinutuzumabIbrutinib
Study Phase: Phase 1
A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Enrollment Status: Active, not recruiting
Publish Date: October 25, 2022
Intervention Type: Drug
Study Drugs: IbrutinibFludarabineCyclophosphamideRituximab
Study Phase: Phase 2
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Enrollment Status: Terminated
Publish Date: December 08, 2022
Intervention Type: Biological, Drug
Study Drugs: Brexucabtagene AutoleucelFludarabineCyclophosphamide
Study Phase: Phase 1
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
Enrollment Status: Active, not recruiting
Publish Date: September 14, 2022
Intervention Type: Drug
Study Drugs: UmbralisibIbrutinib
Study Phase: Phase 1
View 7 Less Clinical Trials -
147 Total Publications
CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 27, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
DD
Daniel J. Deangelo
Dr. Daniel J. Deangelo
Oncology | Hematology Oncology
Highly rated in
38
conditions
Oncology
Hematology Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 

Daniel Deangelo is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Deangelo has been practicing medicine for over 30 years and is highly rated in 38 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Systemic Mastocytosis, Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Deangelo is currently accepting new patients.

EC
Dr. Edwin Choy
Oncology | Hematology Oncology
Highly rated in
34
conditions
Oncology
Hematology Oncology

Mass General Brigham

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 2.7 mi

Edwin Choy is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Choy has been practicing medicine for over 23 years and is highly rated in 34 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Liposarcoma, Bone Tumor, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Choy is currently accepting new patients.

RS
Dr. Richard M. Stone
Hematology Oncology | Hematology | Oncology
Highly rated in
39
conditions
Hematology Oncology
Hematology
Oncology

Dana Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 

Richard Stone is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Stone has been practicing medicine for over 42 years and is highly rated in 39 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Stone is currently accepting new patients.